Wyndly

Wyndly offers a solution for allergy sufferers seeking alternatives to traditional medications. By employing sublingual immunotherapy (SLIT), Wyndly aims to retrain the body to tolerate allergens, providing lasting relief. The company combines the convenience of telehealth and direct-to-consumer care, ensuring a seamless and patient-centric experience. Wyndly's approach focuses on personalized treatment plans developed in consultation with allergy specialists, offering a refreshing alternative to conventional allergy management.

With a significant and growing population affected by allergies, Wyndly addresses a critical need for accessible and effective care. The company envisions expanding its model beyond allergies to encompass other chronic conditions, aiming to improve patient experiences and outcomes in areas like asthma and sleep apnea.

Wyndly is committed to compassion, focus, courage, and progress, driving its mission to transform chronic care. Supported by Y Combinator and other investors, Wyndly is led by Dr. Manan Shah, a telehealth expert, and Aakash Shah, a growth-focused entrepreneur.